Madrid, Spain — September 30, 2025.
In medicine, every piece of data tells a story: a microscopy sample, a lab result, a clinical record. At SpotLab, we believe that connecting all this information through artificial intelligence can transform how diseases are diagnosed and treated.
That’s the purpose behind PROHEMIA, a project co-funded by the Comunidad de Madrid (Ref. A453) and the European Regional Development Fund (FEDER) under the “Support for Innovative SMEs (2023)” program.
Through PROHEMIA, we have developed an AI-based tool that helps predict how patients with hematological diseases such as leukemia or lymphoma will evolve.
Its goal: to enable more informed, personalized, and early clinical decisions. The platform integrates and analyzes multimodal data to provide a comprehensive view of each patient.
One concrete example: thanks to this platform, we have developed a model that predicts whether a patient with hematologic cancer will experience severe side effects from a specific treatment. This allows clinicians to anticipate complications, tailor therapeutic strategies, and improve patient safety from the very beginning.
Developed in collaboration with Hospital 12 de Octubre, the project strengthens our commitment to applying AI to major clinical challenges.
Although its validation has been carried out in the field of hematology, its design is scalable to many other areas of medicine, opening new opportunities to move toward more precise and patient-centered care.
If you’d like to explore an idea with us, get in touch: info@spotlab.ai
